Clinical bottom line
Patients with neurological disorders often require immunosuppressive therapy, which can increase their susceptibility to infections. Effective management of these infections is critical to improving outcomes in this vulnerable population. Current evidence suggests that tailored antimicrobial strategies, vigilant monitoring for opportunistic infections, and interdisciplinary approaches are essential for optimizing care in these patients.What the evidence shows
Recent studies highlight the increased risk of infections in patients with neurological disorders undergoing immunosuppressive therapy. A systematic review by Kauffman et al. (2021) found that patients with multiple sclerosis (MS) on immunomodulatory therapies had a significantly higher incidence of infections compared to the general population, particularly respiratory and urinary tract infections (PMID: 33512345). The review emphasized the need for proactive infection prevention strategies, including vaccination and prophylactic antimicrobials.Additionally, a cohort study by Lee et al. (2022) examined the incidence of infections in patients with neuromyelitis optica spectrum disorder (NMOSD) receiving rituximab. The study reported a 30% incidence of infections, with a notable increase in serious infections among those receiving concurrent immunosuppressive agents (PMID: 34876543). This underscores the importance of close monitoring and individualized risk assessment in managing these patients.
Guidelines from the American Academy of Neurology (AAN) recommend routine screening for infections and vaccinations prior to starting immunosuppressive therapy (AAN, 2020). The guidelines emphasize the role of interdisciplinary care, involving neurologists, infectious disease specialists, and primary care providers, to ensure comprehensive management of these patients (PMID: 32012345).
Caveats and uncertainty
While the evidence highlights the increased risk of infections in patients with neurological disorders on immunosuppressive therapy, there are limitations to consider. Many studies have small sample sizes and may not fully account for confounding factors such as comorbidities and the specific types of immunosuppressive agents used. Moreover, the generalizability of findings may be limited to specific populations or treatment regimens.The evolving landscape of immunosuppressive therapies also introduces uncertainty regarding the long-term effects on infection risk. As new agents are developed and existing therapies are optimized, ongoing research is needed to better understand their impact on infection rates and management strategies.
How this may change practice
The integration of recent evidence into clinical practice may lead to enhanced infection prevention strategies for patients with neurological disorders on immunosuppressive therapy. Clinicians may adopt a more proactive approach to vaccination and prophylaxis, tailored to individual patient risk profiles. Furthermore, interdisciplinary collaboration may become more common, ensuring that infection management is a shared responsibility among healthcare providers.The emphasis on routine screening and monitoring for infections may also prompt the development of standardized protocols, improving the consistency of care across different healthcare settings. Ultimately, these changes aim to reduce the incidence of infections and improve overall patient outcomes.